{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:31:12Z","timestamp":1792528272189,"version":"4.5.0"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["PA19-0084"],"award-info":[{"award-number":["PA19-0084"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Immune checkpoint inhibitor (ICI)-associated immune nephritis or acute interstitial nephritis (AIN) is one of the rare but known complication of ICI therapy. Guidelines recommend treatment of ICI-associated AIN with steroids, then TNF-alpha inhibitor infliximab. However, some cases are refractory to these therapies, potentially due to insufficient cytokine blockade. This is the first case where a 65-year-old female with metastatic lung adenocarcinoma, requiring high maintenance doses of steroids for immune nephritis was treated with tofacitinib, an oral Janus kinase (JAK) inhibitor. Tofacitinib enabled successful steroid tapering and might be a therapy option for refractory immune nephritis.<\/jats:p>","DOI":"10.1093\/ckj\/sfae127","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T01:32:00Z","timestamp":1714095120000},"source":"Crossref","is-referenced-by-count":12,"title":["Tofacitinib for the treatment of refractory immune checkpoint inhibitor-associated immune nephritis"],"prefix":"10.1093","volume":"17","author":[{"given":"Kiran","family":"Shivaraj","sequence":"first","affiliation":[{"name":"Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Tchakarov","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Texas Health Science Center McGovern Medical School , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlan","family":"Dong","sequence":"additional","affiliation":[{"name":"Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7073-9658","authenticated-orcid":false,"given":"Jamie S","family":"Lin","sequence":"additional","affiliation":[{"name":"Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"2024052712390527600_bib1","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1056\/NEJMc2002527","article-title":"Tofacitinib for refractory immune-related colitis from PD-1 therapy","volume":"382","author":"Esfahani","year":"2020","journal-title":"N Engl J Med"},{"key":"2024052712390527600_bib2","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1177\/1078155220947141","article-title":"Tofacitinib for treatment in immune-mediated myocarditis: the first reported cases","volume":"27","author":"Liu","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"2024052712390527600_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2023.12.011","article-title":"Tofacitinib is effective in treating refractory immune checkpoint inhibitor hepatitis","author":"Wang","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024052712390527600_bib4","first-page":"e165108","article-title":"Tertiary lymphoid structure signatures are associated with immune checkpoint inhibitor related acute interstitial nephritis","author":"Singh","year":"2022  1","journal-title":"JCI Insight"},{"key":"2024052712390527600_bib5","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021  26","journal-title":"Sig Transduct Target Ther"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae127\/57335190\/sfae127.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/5\/sfae127\/57925558\/sfae127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/5\/sfae127\/57925558\/sfae127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T12:39:46Z","timestamp":1716813586000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfae127\/7658454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":5,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfae127","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,4,25]]},"article-number":"sfae127"}}